Pharmaceutical Executive

By Pharmaceutical Executive PodcastScience Life Sciences

Pharmaceutical Executive episodes

April 17 Inside Pharma's Revenue Engine: The Gross-to-Net Reckoning
In the debut episode of Pricing & Policy with Model N — a new podcast series from Pharmaceutical Executive — Model N VP of product management Michael Grosberg joins host Mike Christel to break down what the company's annual state of revenue survey reveals about the mounting pressures threatening pharma's commercial foundation. From PBM opacity and Medicaid withdrawal to "ghost claims" lurking inside DTC channels, this conversation pulls back the curtain on the industry's most consequential — and perhaps least understood — business challenge: revenue management.
01:50 - Drivers of rising GTN complexity.
05:08 - The Medicaid dilemma: Exiting the program.
08:30 - Coordination of benefits and rebate eligibility: “We’re doing a really poor job at this.”
10:57 - The easiest way to solve the problem.
12:04 - IRA’s Medicare drug price negotiations: Where we stand.
16:20 - Launch strategy and sequencing considerations.
20:13 - MFN agreements transparency.
21:51 - Data disconnect blurs pricing and revenue visibility.
24:05 - AI "catch-up" imperatives for revenue management.
27:48 - System strain? DTC’s downstream impacts.
33:36 - Top threats to future model.
37 min
April 16 Pharmaceutical Executive Daily: Eli Lilly Releases Updated Safety Data for Foundayo
In today's Pharmaceutical Executive Daily, Eli Lilly releases updated safety data for its oral obesity pill Foundayo in response to an FDA post-approval request, ICER and Verdant Research publish a new white paper examining the evolution and future of the FDA's accelerated approval pathway, and a new Pharmaceutical Executive commentary argues FDA's shift toward single-trial approval standards marks the beginning of a genuinely new era in data-driven drug development.
3 min
April 15 Pharmaceutical Executive Daily: Obsidian and Galera Therapeutics Enter Merger Agreement
In today’s Pharmaceutical Executive Daily, platform innovation continues to drive biotech investment across oncology and immunology, Obsidian Therapeutics and Galera Therapeutics enter a $350 million merger agreement, and industry leaders explore a new standard for copay program excellence.
2 min
April 14 Pharmaceutical Executive Daily: AbbVie and Haisco Enter $745 Million Licensing Agreement
In today's Pharmaceutical Executive Daily, AbbVie licenses a portfolio of pain compounds from China's Haisco Pharmaceutical in a deal worth up to $745 million, the FDA grants full approval to Filspari as the first and only approved treatment for focal segmental glomerulosclerosis, and Pharmaceutical Executive speaks with Deepak Prakash of Identiv on how RFID and real-time tracking are building operational visibility in clinical trials.
3 min
April 13 Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
In today's Pharmaceutical Executive Daily, the FDA issues a second complete response letter for Replimune's RP1 in advanced melanoma, Regeneron and Telix Pharmaceuticals announce a radiopharmaceutical collaboration worth up to $2.1 billion, and Pharmaceutical Executive speaks with Matt Holms of Citeline on improving patient experience and real-world evidence integration in clinical trials.
3 min
April 10 Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer
In today's Pharmaceutical Executive Daily, China approves Amgen's tarlatamab for previously treated extensive-stage small cell lung cancer, a large study identifies genetic predictors of GLP-1 weight loss efficacy and side effects, and Pharmaceutical Executive speaks with Phenomix CEO Mark Bagnall on the complex realities of GLP-1 usage that many patients don't anticipate.
4 min
April 10Why Branding is Pharma’s Most Undervalued Asset
In this episode of Leading Edge With Ken Banta, The Vanguard Network founder and CEO is joined by branding strategist Andy Milligan, founding partner of The Caffeine Partnership, where the duo examine why life sciences companies urgently need to rethink how they build, protect, and communicate their brands.
Highlights of the discussion include:
Relevance + consistency = brand durability
Trust is pharma’s defining — and fragile — currency
The science-to-experience disconnect
Storytelling as a strategic lever, especially in rare disease
24 min
April 09 Pharmaceutical Executive Daily: Shionogi Receives a Contract Through BARDA's Project BioShield
In today's Pharmaceutical Executive Daily, Shionogi receives a contract worth up to $482 million to bolster U.S. preparedness against drug-resistant bacterial threats, Roche and C4 Therapeutics expand their long-standing partnership into a new collaboration to develop degrader-antibody conjugates for oncology, and Pharmaceutical Executive profiles AstraZeneca CFO Aradhana Sarin on how she approaches the role as a strategic catalyst for growth.
3 min
April 08 Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
In today's Pharmaceutical Executive Daily, activist investor Shah Capital escalates its campaign against Novavax's board ahead of the company's annual meeting, a Louisiana federal judge declines to block mail-order access to mifepristone while leaving open the possibility of a future ruling against it, and a Q&A examines how the pharmaceutical industry is navigating the compounding pressures of the Iran war and tariff uncertainty on global supply chains.
3 min
April 07 Pharmaceutical Executive Daily: Wegovy HD Now Available in the U.S.
In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.
4 min